Form 4: Alkermes Executive Christian Todd Nichols Reports Stock Transactions
SEC Form 4 Filing
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reports the acquisition and disposal of ordinary shares and derivative securities.
Summary
- Christian Todd Nichols, a senior executive at Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
- On February 23, 2024, Nichols acquired 6,407 ordinary shares through the vesting of restricted stock units and disposed of 2,845 shares to cover tax obligations at a price of $29.57.
- Following these transactions, Nichols directly owns 76,328 ordinary shares.
- On February 26, 2024, Nichols was granted an option to buy 87,602 ordinary shares at $30.04, which vests in four equal annual installments commencing on February 26, 2025, and 21,638 restricted stock units, which vest in four equal annual installments commencing on February 26, 2025.
- After these transactions, Nichols directly owns 19,223 restricted stock units and 87,602 employee stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The document does not contain explicit forward-looking statements, but it outlines the vesting schedules for stock options and restricted stock units, indicating future equity-based compensation for the reporting person.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted stock units are standard practice in the pharmaceutical industry to align management's interests with those of shareholders.
- Vesting schedules of four years are common for such equity grants, incentivizing long-term commitment.
- Comparing the size of the grants to those of executives at similar-sized pharmaceutical companies (e.g., Teva, Mylan) would provide further context on the competitiveness of Alkermes' compensation practices.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the executive's holdings and incentives.
- The vesting schedules for stock options and restricted stock units could impact employee morale and retention.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Acquisition of 6,407 ordinary shares through vesting of restricted stock units and disposal of 2,845 shares for tax obligations. |
| 02/26/2024 | Grant of stock option to buy 87,602 ordinary shares and grant of 21,638 restricted stock units. |
| 02/26/2025 | Commencement of vesting for stock options and restricted stock units in four equal annual installments. |
| 02/26/2034 | Expiration date of the employee stock options. |
| 02/27/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.